Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Article Page

Abstract

Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

Keywords: bevacizumab, checkpoint inhibitor, chemotherapy, ovarian cancer, PARP inhibitor

Citation: Liu MC, Tewari KS. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs in Context 2018; 7: 212558. DOI: 10.7573/dic.212558

Contributions: This article was written and edited by both authors.

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/11/dic.212558-COI.pdf

Acknowledgments: None.

Funding declaration: No funding was received for this work from the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute or any other source.

Copyright: Copyright © 2018 Liu MC, Tewari KS. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Liu MC, Tewari KS. https://doi.org/10.7573/dic.212558. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/antiangiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancer

Correspondence: Krishnansu S Tewari, University of California, Irvine, 333 City Blvd West, Suite 1400, Orange, CA 92868, USA. ktewari@uci.edu

Provenance: invited; externally peer reviewed.

Submitted: 12 September 2018; Peer review comments to author: 30 October 2018; Revised manuscript received: 18 November 2018; Accepted: 22 November 2018; Publication date: 27 December 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF